DNL126 is an investigational enzyme replacement therapy designed to cross the BBB for the potential treatment of MPS IIIA (Sanfilippo syndrome type A).
Denali Therapeutics Says FDA Has Selected DNL126 For Participation In Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.